Table 2.

Comparison of CT findings and scores between two groups in patients with COVID-19

Variables	Early-stage group (n = 34)	Progressive-stage group (n = 28)	p value
CT findings
Ground-glass opacity	22 (64.7%)	16 (57.1%)	0.543 (χ)
Consolidation	1 (2.9%)	0 (0%)	1.000 (χ)
Ground-glass opacity with consolidation	11 (32.4%)	11 (39.3%)	0.570 (χ)
Reticular pattern	0	0	–
Nodule	1 (2.9%)	0	1.000 (χ)
Rounded opacities	10 (29.4%)	6 (21.4%)	0.475 (χ)
Cavitation	0	0	–
Crazy-paving pattern	8 (23.5%)	8 (28.6%)	0.652 (χ)
Air bronchogram	8 (23.5%)	6 (21.4%)	0.844 (χ)
Halo sign	7 (20.6%)	0	0.013 (χ)
Bronchial wall thickening	0	0	–
Subpleural curvilinear line	4 (11.8%)	2 (7.1%)	0.681 (χ)
Thoracic lymphadenopathy	0	1 (3.6%)	0.452 (χ)
Pleural effusion or thickening	1 (2.9%)	1 (3.6%)	1.000 (χ)
Pulmonary fibrosis	0	1 (3.6%)	0.452 (χ)
Max diameter of lesion (cm)	4.27 ± 2.66	5.83 ± 3.76	0.059
< 1 cm	0	1 (3.6)	0.201 (χ)
1–2.9 cm	13 (38.2%)	5 (17.9%)
3–4.9 cm	12 (35.3%)	10 (35.7%)
> 5 cm	9 (26.5%)	12 (42.9%)
Distribution
Central	1 (2.9%)	1 (3.6%)	0.961 (χ)
Peripheral	12 (35.3%)	9 (32.1%)
Both central and peripheral	21 (61.8%)	18 (64.3%)
CT score	4.79 ± 2.76	7.79 ± 4.62	0.004
0–5	27 (79.4%)	10 (35.7%)	0.004 (χ)
6–10	6 (17.6%)	12 (42.9%)
11–15	0	3 (10.7%)
> 15	1 (2.9%)	3 (10.7%)

COVID-19, coronavirus disease 2019